You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
|
|---|---|
| Published in |
Journal of Translational Medicine, November 2011
|
| DOI | 10.1186/1479-5876-9-204 |
| Pubmed ID | |
| Authors |
Omid Hamid, Henrik Schmidt, Aviram Nissan, Laura Ridolfi, Steinar Aamdal, Johan Hansson, Michele Guida, David M Hyams, Henry Gómez, Lars Bastholt, Scott D Chasalow, David Berman |
| Abstract |
Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor microenvironment for associations with clinical response to ipilimumab. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 389 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Finland | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Unknown | 385 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 77 | 20% |
| Student > Ph. D. Student | 57 | 15% |
| Student > Master | 39 | 10% |
| Other | 36 | 9% |
| Student > Bachelor | 36 | 9% |
| Other | 59 | 15% |
| Unknown | 85 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 121 | 31% |
| Agricultural and Biological Sciences | 58 | 15% |
| Biochemistry, Genetics and Molecular Biology | 46 | 12% |
| Immunology and Microbiology | 31 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 2% |
| Other | 31 | 8% |
| Unknown | 94 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,514,243
of 23,443,716 outputs
Outputs from Journal of Translational Medicine
#256
of 4,156 outputs
Outputs of similar age
#10,600
of 243,710 outputs
Outputs of similar age from Journal of Translational Medicine
#2
of 59 outputs
Altmetric has tracked 23,443,716 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,710 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.